For Healthcare Professionals

First-in-Human Study of EOS100850 in Patients With Cancer


About the study

Multicenter, open-label, dose-escalation Phase I/Ib clinical study to evaluate the safety and tolerability, the MTD/RP2D, pharmacokinetics (PK), pharmacodynamics (PD), and antitumor activity of EOS100850 as a Single Agent and in Combination with Pembrolizumab and/or Chemotherapy in Participants with Advanced Cancers.

Who can take part

You may be eligible to participate in the study if you meet the following criteria:


  • For more information regarding participation in the Trial, please refer to your physician
  • Inclusion Criteria:

    1. Women and men ≥18 years of age with Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
    2. Subject with histologically or cytologically confirmed advanced solid tumor for whom no standard treatment is further available.
    3. At least 4 weeks since any previous treatment for cancer
    4. Subject must consent to pretreatment and on treatment tumor biopsies
    5. Adequate organ and marrow function


    Exclusion Criteria:

    1. Patients with primary brain tumors or primary tumors with central nervous system metastases as only location of disease. Controlled brain metastases are permitted
    2. Participants with second/other active cancers requiring current treatment
    3. Uncontrolled/significant heart disease
    4. Known History of chronic hepatitis, Positive test for Hepatitis B virus surface antigen or Hepatitis C antibody (except participants with liver cancer) or Human Immunodeficiency Virus/Acquired Immunodeficiency Syndrome(HIV/AIDS)
    5. Active/uncontrolled autoimmune disease
    6. Active infection

    Other protocol defined inclusion/exclusion criteria could apply

    pin location

    Study Locations

    Enter your ZIP code/Postal code/PIN code to locate study sites near you:

    How to Apply

    Contact the study center to learn if this study is a good match for you.

    Study’s details


    Solid Tumor, Adult

    Age (in years)



    Phase 1

    Participants needed


    Est. Completion Date

    Jul 31, 2024

    Treatment type



    iTeos Therapeutics identifier


    Study number


    Understanding Clinical Trials

    Get answers to your questions about clinical trials.What is a clinical research?What does taking part in clinical trials involve?What should I ask the trial doctor?


    Sign up to save your favorites, 
    receive newsletters, resources, and alerts 
    about clinical trials related to your conditions of interest.